Clincosm LogoSign in Get a demo

CAMPHIBIII: Characterizing the cerebrovAscular Physiology of Optimal Mean Arterial Pressure Targeted Resuscitation

Sponsor
University of British Columbia (Other)
Overall Status
Completed
CT.gov ID
NCT03609333
Collaborator
(none)
20
Enrollment
1
Location
1
Arm
43.6
Actual Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Hypoxic ischemic brain injury is a devastating illness that occurs after cardiac arrest (the heart stopping) and can yield irreversible brain damage, often leading to death. The mainstay in therapy is to optimize the delivery of oxygen to the brain to help it recover. In patients with traumatic brain injury (similar to HIBI), the investigators are able to optimize oxygen delivery to the brain with the use of wires placed into the brain that sense the pressure and oxygen in the skull to find the ideal blood pressure for each individual patient. This strategy is associated with improved outcomes. The investigators are conducting a prospective study investigating whether the perfusion within proximity to the optimal MAP is associated with improved brain oxygenation and blood flow .

Condition or Disease Intervention/Treatment Phase
  • Device: Multimodal Neuromonitoring
 N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Primary Purpose:
Basic Science
Official Title:
Characterizing the cerebrovAscular Physiology of Optimal Mean Arterial Pressure Targeted Resuscitation in Hypoxic Ischemic Brain Injury After Cardiac Arrest
Actual Study Start Date :
Nov 12, 2016
Actual Primary Completion Date :
Jun 30, 2020
Actual Study Completion Date :
Jun 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Internal arm

Device: Multimodal Neuromonitoring
Application of multimodal neuromonitoring
Other Names:
  • Targeted optimal MAP resuscitation

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Cerberal blood flow [12 hours]

      mls/100g/min

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Confirmed cardiac arrest with return of spontaneous circulation > 10 minutes

    • post resuscitation GCS < 9

    Exclusion Criteria:

    • concurrent coagulopathy

    • prior history of TBI, intracranial hemorrhage, subarachnoid hemorrhage

    • anticipated cardiac catheterization within next 7 days

    • anticipated or current use of anticoagulants or anit-platelets

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Vancouver General Hospital Vancouver British Columbia Canada V5Z 1M9

    Sponsors and Collaborators

    • University of British Columbia

    Investigators

    • Principal Investigator: Mypinder Sekhon, MD, UBC

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Myp Sekhon, Principal Investigator, University of British Columbia
    ClinicalTrials.gov Identifier:
    NCT03609333
    Other Study ID Numbers:
    • H16-00466
    First Posted:
    Aug 1, 2018
    Last Update Posted:
    Nov 3, 2020
    Last Verified:
    Nov 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Heart Arrest

    Study Results

    No Results Posted as of Nov 3, 2020